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Abstract 
Nature has provided prodigious reservoirs of pharmacologically active compounds for drug 
development since times. Physcion and physcion 8-O-β-D-glucopyranoside (PG) are bioactive 
natural anthraquinones which exert anti-inflammatory and anti-cancer properties with minimum 
or no adverse effects. Moreover, physcion also exhibits anti-microbial and hepatoprotective 
properties while PG is known to have anti-sepsis as well as ameliorative activities against 
dementia. This review aims to highlight the natural sources and anti-cancer activities of physcion 
and PG along with associated mechanisms of actions. On the basis of the literature, physcion and 
PG regulate multitudinous cell signaling pathways through the modulation of various regulators 
of cell cycle, protein kinases, microRNAs, transcriptional factors, and apoptosis linked proteins 
resulting in the effective killing of cancerous cells in vitro as well as in vivo. Both compounds 
effectively suppress metastasis, furthermore, physcion acts as inhibitor of 6PGD and also play an 
important role in chemosensitization. This review article suggests that physcion and PG are 
potent anti-cancer drug candidates but further investigations on their mechanism of action and 
pre-clinical trials are mandatory in order to comprehend the full potential of these natural cancer 
killers in anti-cancer remedies. 











Natural products (NPs) are biologically active chemical substances produced by living organisms 
having molecular weight lower than 3000 Da [1]. NPs have been proven to be valuable source 
for drug development [2-3]. They can attain the same level of effectiveness as synthetic drugs, 
are safer to use for prolonged period of time and are reported to have fewer side effects [4-5]. 
The earliest records of plant-based medicinal system date back to 2600 BC, which reports the use 
of around 1000 plant-derived drugs in Mesopotamia. The Ebers Papyrus also records the 
utilization of more than 700 drugs, majority of which belongs to plants. The Chinese Materia 
Medica and Indian Ayurveda system have been reported extensively over centuries for their 
medicinal values [6]. Historically, all the medicinal preparations were acquired through NPs. 
Recently natural products have provided number of lead compounds for development of anti-
microbial and anti-cancer agents. From 1981-2010, about 34% of the drugs sanctioned by the 
FDA were either natural products or their derivatives [7]. 
Natural products play vital role in the discovery of new anti-cancer agents. Most of the natural 
anti-cancer agents have a wide spectrum of molecular targets as compared to the mono-targeted 
synthetic anti-cancer drugs [8]. Almost 50% of the approved anti-cancer drugs between 1940-
2014 are either directly acquired from natural sources or their synthetic derivatives [9]. 
Vincristine, vinblastine, etoposide phosphate, vinflunine, paclitaxel, homoharringtonine, 
vincristine sulfate, and topotecan are some examples of anti-cancer drugs from plant origin [10-
12] while anthracyclines, bleomycin, dactinomicine and mitomycin are microbial-derived anti-
cancer agents [13]. Citarabine, aplidine, bryostatin-1, ET-743, and dolastatin 10  are examples of 
anti-cancer agents obtained from marine sources [14-15], all of which highlights the immense 
significance of NPs in drug discovery. 
Nature derived phenolic compounds such as flavonoids, carotenoids and tannins are bioactive 
entities with versatile pharmacological properties [16-17]. Anthraquinones are the derivatives of 
1,8-dihydroxyanthrone which belongs to the class of phenolic compounds [18]. Anthraquinone 
enriched plants like rhubarb have been utilized in folk medicine for centuries. Anthraquinone 
derivatives exhibit several pharmacological activities such as antifungal, anti-viral, anti-bacterial, 
anti-oxidant, anti-platelet, and anti-cancer. They also have the capability to cure multiple 
sclerosis and malaria [19-21].  
 
To date, no review is available on the anti-cancer potential of natural anthraquinones, physcion 
and physcion 8-O-β-D-glucopyranoside (PG). This review aims to summarize the studies 
relevant to the pharmacological efficacy of physcion and PG against different cancer types. It is 
speculated that the accumulated data will pave a path for researchers towards the development of 
these natural compounds into pharmacological drugs in the future. The literature was collected 
through various e-sites such as Elsevier Science Direct, Springer Link, Scopus, PubMed, and 
other medical linked journals. Keywords used for searching were “Natural products”, 
“Physcion”, “Physcion 8-O-β-D-glucopyranoside (PG)”, “Anti-cancer activity” and “Antitumor 
effect”. 
2. Natural sources of physcion and PG 
Physcion has been isolated from Rheum tanguticum [22], Rheum palmatum [23] or Radix et 
Rhizoma Rhei [24-26], Rheum emodi [27], Rhamnus sphaerosperma var. pubescens [28], 
Polygonum multiflorum [29], Frangula rupestris [21], Muehlenbeckia hastulata [30], Reynoutria 
elliptica [31], Anethum sowa [32], Vismia rubescens [33], Ventilago madraspatana Gaertn. [34], 
Cassia tora [35], Cassia alata [36], Cassia javanica, Cassia accutifolia, Cassia biflora, Cassia 
italic, Cassia spectabilis, Cassia sophera, Cassia renigera [37], Rumex crispus [38], Osmunda 
japonica [39], marine fungus Microsporum sp. [19, 29, 40], and sponge associated fungus 
Eurotium cristatum [41]. Along with many important herbs like Vitis vinifera, Plantagines 
lanceolatae and Rhizoma graminis, physcion is also found in many vegetables such as beans, 
cabbage lettuce and peas [42] (Table 1) (Figure 1). 
Table 1. Natural sources of physcion and their parts used 
Name of Plants 
Parts used References 
Scientific Name Common Name 
Anethum sowa Dill Roots [32] 
Polygonum multiflorum He shou wu, Tuber fleece flower Dried roots [29] 
Rheum emodi Revand-chini, Himalayan rhubarb Rhizome [27] 
Rheum palmatum Turkey rhubarb, Chinese rhubarb Rhizome [23-26] 
Rheum tanguticum Rhubarb Rhizome [22] 
Rheum dentatus Toothed dock Roots [43] 
Ventilago madraspatana Red creeper Stem bark [34] 





Dried stem [28] 
Cassia javanica Pink shower Leaves [37] 
 
Cassia tora Sickle Senna Seeds [35, 37] 
Cassia alata Candle bush Roots [36-37] 
Rumex crispus Curly dock --- [38] 
Osmunda japonica Asian royal fern --- [39] 
Frangula rupestris --- Stem bark [21] 
Vismia rubescens --- Stem bark [33] 
Eurotium cristatum --- --- [41] 
Reynoutria elliptica Asian knotweed --- [31] 
Microsporum sp --- --- [19, 29, 40] 
Vitis vinifera Grape vine Leaves [42] 
Latuca sativa var. 
capitate 
Cabbage lettuce Leaves [42] 
 
Figure 1. Natural sources and chemical structure of physcion 
PG is a biologically active component of Rheum palmatum[44], Rheum officinale, Polygonum 
multiflorum, Polygonum reynoutria [45], Polygonum cuspidatum [46], Reynoutria sachalinensis 
[47], Fallopia sachalinensis [48] and Rumex japonicus Houtt (Figure 2) [49-52].  
 
Table 2. Natural sources of PG and their parts used 
Name of Plants 
Parts used References 
Scientific Name Common Name 
Rheum palmatum Turkey rhubarb, Chinese rhubarb Roots [44] 
Rheum officinale Chinese rhubarb, Indian rhubarb Roots [45] 
Polygonum multiflorum He shou wu, Tuber fleece flower Roots [45] 
Polygonum reynoutria Japanese knotweed Roots [45] 
Polygonum cuspidatum Peashooter plant, Huzhang Roots [46] 
Reynoutria sachalinensis Giant knotweed Flowers [47] 
Fallopia sachalinensis Giant knotweed Rhizome [48] 
Cassia obtusifolia Sicklepod Seeds [37] 
Cassia occidentalis Coffee senna Seeds [37] 




Figure 2. Natural sources and chemical structure of PG 
  
 
3. Biological activities of physcion and PG 
The biologically and pharmacologically active anthraquinones, physcion and PG have been well-
known for their potential anti-cancer [19, 22-23, 28, 49, 51] and anti-inflammatory activities [34, 
53]. Moreover, physcion also shows anti-microbial [33] and hepatoprotective properties [54] 
while PG displays ameliorative effects against dementia [46] and have anti-sepsis properties 
[55]. This review spotlights on the mechanism by which both these compounds act to combat 
cancer progression.  
3.1 Anti-cancer activity 
Cancer is a multifaceted malady encompassing genetic, signaling and metabolic aberrations that 
remarkably disturb cellular homeostasis [56]. It is the 2nd leading cause of mortalities worldwide 
with approximately 9.6 million cancer-associated deaths reported in 2018 [57]. Currently 
available treatments for cancer are based on chemotherapeutic drugs which have limited clinical 
effectiveness due to high toxicity and poor selectivity which arouse the ultimate demand for 
safer, reliable and cheap anti-cancer drugs [58]. NPs have been utilized since ancient times for 
the management of several ailments including cancer. Therapeutic potential of NPs against 
cancer is associated with prohibiting angiogenesis, halting metastasis, inducing cell cycle arrest, 
activating tumor suppressor genes as well as regulating cell signaling pathways [59-61]. 
Chemoprevention by naturally occurring entities specifically phytochemicals has turned up as 
auspicious and pragmatic strategy to decrease the risk of cancer and this area of research is 
gaining attention [62]. These natural bioactive entities are multi-targeted having promising 
competency to halt cancer growth and development as compared to monotarget-synthetic drugs,  
[63]. 
Anthraquinones comprise a large class of natural bioactive compounds with their broad spectrum 
of applications in the biological systems [18]. Approximately 700 varied anthraquinone 
derivatives have been reported, out of which 200 belongs to medicinal plants. Anthraquinone 
monomers like rhein, emodin, chrysophanol, physcion, hypericin, and aloe-emodin are gaining 
attentiveness due to their excellent medicinal competency against pathological conditions such as 
cancer. The anti-cancer properties of many anthraquinones are influenced by the substituents 
present on anthraquinone ring. For single anthraquinone, the position of OH-group (C-8 and -5) 
may play a vital role in its anti-tumor activity and hydroxylation at C-1 position can 
subsequently increase its cytotoxicity suggesting that the phenolic OH-groups contribute towards 
 
the anti-cancer potential of anthraquinones [20]. Anthraquinones including physcion and PG 
exert their anti-cancer effects by suppressing the growth of cancerous cells, reprograming cancer 
cell metabolism, inhibiting metastasis, triggering apoptosis, inducing cell cycle arrest, regulating 
various signaling pathways, and improving efficacy of chemo drugs in drug resistance cancer 
cells [18, 20, 64]. 
3.1.1 Induction of cell cycle arrest 
Cell cycle progression from one phase towards the next is predominantly regulated by cyclins 
and cyclin-dependent kinases (CDKs). The amount of CDKs throughout the cell cycle remains 
relatively stable, whereas cyclins’ concentration rises or falls during different stages of the cell 
cycle [65]. Cyclin H binds to CDK7 which serves as a CDK activating kinase. Cyclin D1/D2/D3 
bind to CDK4 and 6 and this CDK-cyclin D network is indispensable for entrance into the G1 
phase. Cyclin E binds to CDK2 and controls advancement from G1 into S-phase. For S-phase, 
Cyclin A-CDK2 complex is essential. Cyclin A binds with CDK1 during late G2 and initial 
mitotic phase to promote entry into it. Cyclin B in complex with CDK1 further regulates mitosis 
[66].  
Physcion and PG have been reported to halt cell cycle at G0/G1 and G2/M phases in many 
cancer cells. Physcion arrested HCT116 cells at G0/G1 phase via downregulating cyclin D1 and 
E [67]. Physcion treatment led to the reduction in cyclin A/D/E, cyclin-dependent kinases 2 and 
4, PCNA, elevation of p21 and suppression of c-Myc and p-Rb, ultimately arresting the cell 
cycle at G0/G1 in MDA-MB-231 breast cancerous cells [22]. SGC-7901 cells treated with 
physcion reduced cyclin A and B1 expression causing cell cycle arrest at G2/M phase [68]. 
Physcion led CNE2 cells to G1 phase arrest via enhanced p21/27 expression and reduced cyclin 
D1 and cyclin E expression [26]. It repressed HOXA5 (Homeobox A5) expression which 
resulted in cyclin D1 reduction and cell cycle arrest at G1 phase in NALM6 and SUPB15 cells 
[25]. Physcion up-regulated the level of p21 in HeLa cells which ultimately leads to cell cycle 
arrest [19]. 
In NALM6 and SupB15 cells, PG caused cell cycle arrest at G0/G1 phase due to SphK1 
suppression and downregulating cyclin A and cyclin D1 while upregulating p27 and p21 
expression [69]. G1 phase arrest in HepG2 cell line by PG was linked with a decrease in the level 
of cyclin D1 and cyclin E and elevated p21 and p27 expression [70]. PG possesses the capacity 
to halt cell cycle at G1 phase in glioblastoma U87 and U251 cells [51]. PG significantly lowered 
 
the level of cyclin D1, CDK4 and CDK6 eventually arresting cells at G1/G0 phase in A549 and 
H358 cells [71]. PG arrested A549 lung cancer cells at G2/M phase by decreasing the levels of 
cyclin B1 and cdc2 [72] while in case of renal cancer cells by decreasing cyclin B1 and 
increasing CDK2 level [73]. Although physcion and PG has been reported to halt cell cycle at 
G2/M or G0/G1 phase, however, whether at G2, M, G0 or G1 needs to be investigated. 
Furthermore, whether physcion and PG directly targets p21 or via its upstream mediator, p53, 
also needs to be studied in future investigations.  
3.1.2 Induction of apoptosis 
In response to various stimuli, cells undergo a programmed death or apoptosis [74]. Apoptosis is 
designated by distinctive biochemical and morphological alterations involving chromatin 
condensation, shrinkage of nucleus, plasma membrane blebbing, and oligonucleosomal DNA 
fragmentation [75-76]. A number of pathophysiological and physiological stimuli can induce 
apoptosis like TNF-α (tumor necrosis factor-α) [77], CD95 (cluster of differentiation 95) [78], 
UV radiations [79], oxidative stress [80], ceramide treatment [81], growth factors [82], bacteria 
[83] as well as cytotoxic drugs [84-86].  
Two significant pathways are mainly involved in the activation of apoptosis, classified as 
extrinsic and intrinsic pathways [76]. These pathways stimulate activation of pioneer caspases 
(caspase-8, -9, and -12) that in turn activate executioner caspases which cleave target proteins 
leading to the cell death [87-88]. Physcion has been documented to trigger apoptosis in different 
cancer cell lines including MDA-MB-231 [22], HeLa [19], HCT116 [67], SGC-7901 [68], 
NALM6, SUPB15 [25], Huh7, Bel7402 [40], SMMC7721, Hep3B [23], and in CNE2 cells [26] 
(Table 2a). PG has been documented to stimulate apoptosis in several cancerous cells such as 
MG-63 [52], NALM6, SupB15 [69], SMMC7721, HepG2 [24], SMMC7721, BEL7402 [89], 
H358, A549 [58, [72], RCC4, ACHN [73], and in KB cells [90] (Table 2b).  
3.1.2.1 Intrinsic apoptotic pathway 
Mitochondria plays key role in induction of apoptosis through modulation of Bcl-2 (B-cell 
lymphoma 2) family members [91]. The role of Bcl-2 family is significant in apoptosis as it 
contains pro-apoptotic and anti-apoptotic proteins. The ratio of Bcl-2 to Bax (Bcl-2-associated x 
protein) has a critical role in determining the fate of cell [92]. Apoptosis resistance and tumor 
cell survival are correlated in many cancers due to an increased proportion of anti- to pro-
apoptotic Bcl-2 proteins [93]. Controlling the discharge of cytosolic cytochrome c from 
 
mitochondria has been the primary mechanism of Bcl-2 family members for apoptosis 
regulation. Elevated expression of anti-apoptotic proteins forbids the loss of cytochrome c while 
pro-apoptotic proteins induce cytochrome c release [91]. The stimuli result in mitochondria outer 
membrane permeabilisation (MOMP) leading towards the discharge of cytochrome c. 
Cytochrome c oligomerises APAF-1 (apoptotic protease activating factor 1) to generate 
apoptosome that activates procaspase-9 and then activates effector caspase-3/-7. These effector 
caspases in turn cleave many substrates causing cell death. Cancer cells prevent MOMP via up-
regulating the level of Bcl-2 by various mechanisms like microRNAs down-regulation or 
transcriptional up-regulation by oncogenic signaling [94]. Moreover, Smac/DIABLO (second 
mitochondria-derived activator of caspase/direct inhibitor of apoptosis protein (IAP)-binding 
protein with low PI) released from the mitochondria to cytosol interact with anti-apoptotic XIAP 
(X-linked inhibitor of apoptosis) protein antagonizing its effect, which normally binds with 
caspases-3, -7 and -9 via IAP repeat domain and prevent heedless activation of caspases [95]. 
Physcion results in the down-regulation of Bcl-2 [19, 22-23, 25] and Ras [96], up-regulation  of 
Bax [19, 23, 25, 96], loss of MMP (mitochondrial membrane potential) [19, 40, 67-68], opening 
of MPT (mitochondrial permeability transition) pore [40], release of cytochrome c to the cytosol 
[26, 40, 67-68], enhanced expression of activated caspase-3 and -9 [19, 22-23, 25, 40, 67-68, 96], 
and cleaved PARP (Poly (ADP-ribose) polymerase) [25-26, 40] resulting in apoptosis. PG causes 
up-regulation of Bax and decrease in Bcl-2 level [69, 72], loss of MMP, cytosolic release of 
cytochrome c [52, 70, 90], increased caspase-9 and -3 activation [52, 69-72, 89-90], increased 
level of cleaved caspase-7 [72], and PARP activation [52, 69, 71, 89] leading to apoptosis. 
Whether physcion and PG targets other members of Bcl-2 family proteins such as Bak and Bad 
to induce apoptosis should be investigated in future researches.  
3.1.2.2 Extrinsic apoptotic pathway 
Death ligands from the family of TNF bind to their associated receptors at the surface of cell to 
initiate extrinsic apoptotic pathway. Upon binding, they form a death inducing signaling network 
which activates caspase-8 and then caspase-8 cleaves procaspase-3 ensuing apoptosis [97]. In 
addition to intrinsic pathway, physcion also induces apoptosis in nasopharyngeal CNE2 cell line 
via extrinsic pathway which is obvious by increased expression of Fas, DR5 (death receptor-5), 
TRAIL (TNF-related apoptosis-inducing ligand), and caspase-8 [26]. Down-regulation of Bid 
(BH3 interacting domain death agonist) and increased caspase-8 activity by physcion is also 
 
found in MDA-MB-231 and PC3 cells along with increased caspase-9 expression [22, 96]. 
Together with intrinsic pathway activation, PG activates extrinsic apoptotic pathway in HepG2 
cells evident from caspase-8 activation and increased DR4 and TRAIL expression although the 
levels of Fas and DR5 remain the same [70].  
3.1.2.3 Role of ROS and microRNAs in physcion and PG induced apoptosis 
Various studies have documented that excess ROS production causes oxidative stress which 
disturbs intracellular redox status and leads to mitochondria mediated apoptosis in cancer cells 
[98-99]. In cancerous cells, a slight escalation in ROS production can increase drug resistance, 
cell survival and growth, nevertheless, excessive increase of ROS can cause cell cycle arrest and 
apoptosis [100]. The role of ROS in regulating Sp1 (specificity protein 1) expression through 
multiple signaling pathways is evident from several reports. High ROS level modulates Sp1 
expression via activating ERKI/2 (extracellular-signal-regulated kinase) signaling in breast 
cancer [101] and primary human diploid fibroblast cells [102], while activating p38 MAPK 
(mitogen-activated protein kinase) signaling in liver cancerous cells [103].  Suppression of Sp1 
by regulation of miR-27a has also been reported [104]. 
MicroRNAs work either as tumor suppressors or oncogenes. They control different cellular 
processes such as proliferation, differentiation, apoptosis, and invasion via suppressing target 
genes expression [105]. Besides apoptosis, miRNAs have a critical role in regulating autophagy 
[106]. miR-370 serves as the tumor suppressor in gastric cancer [107], acute myeloid leukemia 
[108] and laryngeal squamous cell carcinoma [109] while have an oncogenic role in wilms tumor 
[110]. miR-124 is documented to be down-regulated in various cancers such as liver [111], 
breast [112] and gastric [113] cancers.  
Physcion caused up-regulation of miR-370 leading to mitochondrial apoptosis in SMMC7721 
and HepG2 cells [24]. Physcion increased intracellular ROS and mediated the miR-27a/ZBTB10 
(zinc finger and BTB domain containing 10) axis by decreasing miR-27a and elevating ZBTB10 
expressions which ultimately down-regulated Sp1 at both mRNA and protein levels in 
nasopharyngeal cancer [26]. In osteosarcoma MG-63 cells, PG treatment resulted in ROS 
production, which reduced the level of miR-27a and in turn up-regulated Sp-repressor ZBTB10. 
miR-27a is found to have a regulatory effect on Sp1. Down-regulation of miR-27a decreased Sp1 
expression which subsequently suppressed EMMPRIN (extracellular matrix metalloproteinase 
inducer) suggesting miR-27a role in PG induced pro-apoptotic effect [52]. PG also decreased the 
 
expression of miR-21 in KB cells which then up-regulated PTEN (phosphatase and tensin 
homolog) expression and reduced p-Akt and p-GSK3β (Ser9) (glycogen synthase kinase 3 beta), 
thus, inactivating Akt/GSK3β signaling and decreasing survivin expression that led towards 
apoptosis [90]. Several studies have shown that down-regulation of survivin also inhibits 
metastasis [114-116], so, possibly PG may have anti-metastatic role in KB cells which needs to 
be investigated. miR-124, which has been down-regulated in malignant melanomas, acts as a 
tumor suppressor gene and RLIP76 (Ral binding protein) mediates its anti-neoplastic effect 
[117]. Over-expression of RLIP76 is reported in various tumors and its down-regulation results 
in the regression of tumor in many models [118]. PG exerts its antitumor effects in A375 and 
SK-MEL-1 cancer cells via up-regulating miR-124 and down-regulating mRNA and protein of 
RLIP76 dose dependently [117]. RLIP76 is also needed for the angiogenesis of solid tumors 
[119], thus, miR-124 may have suppressive function on angiogenesis along with cell 
proliferation and invasion which should be examined in future studies.  
3.1.3 Inhibition of metastasis by physcion and PG 
The metastasis of cancer is a sequential process that includes cancer cells invasion in the 
nearby tissues, their continuance in circulatory system, penetration in blood or/and lymphatic 
vessel’s wall, and macroscopic secondary tumor growth in the far-away organs [120]. Natural 
products have turned up as potential reservoirs of anti-metastatic agents. Thus, inhibition of 
migration and invasion capability of malignant cells with natural phytochemicals may provide 
new avenues to cure different types of cancer [121].  
EMT (epithelial–mesenchymal transition) is a major step in metastasis of cancer and β‐catenin 
nuclear translocation is the main feature of EMT [122]. After treating HCT116 and 
MDA‐MB‐231 cells with PG, researchers found aggregation of β‐catenin in the cell membrane 
suggesting EMT inhibition by PG [49-50]. PG reduced the level of transcriptional repressors 
(Snail, Slug and Twist) and mesenchymal markers (N-cadherin, fibronectin, vimentin, α‐SMA) 
in addition to the enhanced expression of epithelial marker (E-cadherin) in MDA‐MB‐231 [49], 
HepG2 [70] and HCT116 cells [50]. These transcriptional repressors have important role in 
regulation of mesenchymal and epithelial markers [123]. PG regulates HIF-1α (hypoxia-
inducible factor-1α) through PTEN/Akt signaling. It caused dose dependent increase in PTEN 
and inhibited Akt activation which in turn down-regulated the protein level of HIF-1α and 
EMMPRIN in HCT116 cells [50].  
 
Physcion prohibited metastasis in colorectal SW620 cancer cells by enhancing E-cadherin 
expression and down-regulating the levels of fibronectin, vimentin, N-cadherin, and α‐SMA 
along with transcriptional repressors Slug, Twist and Snail [124]. Physcion causes the 
suppression of migration in SMMC7721 and Hep3B cells in a dose responsive way by 
decreasing the level of MMP-2/-9 (matrix metalloproteinases) and increasing that of TIMP3 
(tissue inhibitor of metallopeptidase inhibitor 3) [23]. Whether physcion and PG directly interact 
with Snail, Twist and Slug to inhibit their activity or targets their nuclear transport machinery, 
further needs to be investigated.  
3.1.4 Role of AMPK in physcion and PG induced apoptosis and metastasis inhibition 
AMPK (AMP-activated protein kinase) signaling acts as a central switch between apoptosis and 
cell survival. AMPK can inhibit cancer by regulating cell proliferation, cell polarity, cell growth, 
autophagy, and stress feedbacks [125]. Inhibition of proliferation in several cancerous cells has 
been documented by elevating p53, p21Cip and p27Kip through AMPK activation [126]. In 
colorectal HCT116 cells, physcion enhanced AMPK phosphorylation, thus, activating AMPK 
signaling which in turn down-regulated HIF1-α expression and subsequently suppressed 
EMMPRIN, causing increased apoptosis. As physcion represses HIF1-α, it has potential to 
thwart aggressive behavior of tumor cells due to hypoxia and invasion [67]. EMMPRIN is 
enriched at the surface of several malignant cancerous cells and acts as an adhesion molecule 
that promotes invasion and metastasis by inducing secretion of matrix metalloproteinases. Along 
with invasion and metastasis, the link between apoptosis and EMMPRIN has been reported in 
various tumor cells [127-128]. HIF-1α up-regulates EMMPRIN by binding at hypoxia 
responsive element in the promoter region of EMMPRIN [129]. Physcion increased p-AMPK 
which then induced endoplasmic reticulum stress in Bel7402 and Huh7 carcinoma cells. 
Endoplasmic reticulum stress was evident by the increase in p-PERK (protein kinase R (PKR)-
like endoplasmic reticulum kinase), GRP78 (78-kDa glucose-regulated protein), CHOP (C/EBP 
homologous protein), eIF2a (eukaryotic translation initiation factor 2A), ATF6 (activating 
transcription factor 6), and GRP94 (94 kDa glucose-regulated protein) levels along with elevated 
expression of activated caspase-12 (a key indicator of ER stress) proposing that physcion 
triggered intrinsic apoptosis by ER stress via activating AMPK signaling cascade [40]. Physcion 
treatment has potential to up-regulate ROS production in gastric SGC-7901 cells which activates 
AMPK leading to apoptosis [68]. Most of the human genome methylation including anomalous 
 
methylation in cancers occurs by DNMT1 (DNA methyltransferase 1) [130]. DNMT1 
overexpression has been documented in various tumors such as pancreatic [131], hepatocellular 
[132] and non-small cell lung carcinomas [133]. In, SMMC7721 and HepG2 cells, AMPK 
activation by physcion decreases Sp1 expression both at mRNA and protein levels which in turn 
suppress DNMT1 and leads to apoptosis [24]. In glioblastoma U87 and U251 cells, PG exerts its 
anti-tumor effects (apoptotic and anti-invasive) by repressing Skp2 (S-phase kinase-associated 
protein expression) and results in the subsequent up-regulation of p21/p27 which are the 
downstream targets of Skp2. PG treatment enhanced ROS generation with AMPK activation and 
mTOR suppression which indicates the regulation of Skp2 expression by PG via ROS generation 
and modulation of AMPK/mTOR. Either compound C (AMPK inhibitor) or NAC (ROS 
inhibitor) remarkably abolished the suppressing effect of PG on Skp2 expression, showing that it 
regulated the Skp2 expression via modulation of ROS/AMPK/mTOR signaling [51]. 
Several investigations have proven the conflicting role of AMPK in metastasis where AMPK 
signaling inhibits metastasis in some cancers and promotes metastasis in other. AMPK activation 
by metformin in melanoma resulted in the prohibition of invasion and migration [121] while 
lysophosphatidic acid induced AMPK activation enhanced metastasis in ovarian cancer [134]. 
Metastatic potential in SW620 cells is halted by physcion via the down-regulation of SOX2 (Sex 
determining region Y-box 2) which is carried out by the activation of AMPK/GSK3β signaling 
due to intracellular ROS production predominately of hydrogen peroxide [124]. In HepG2 cells, 
PG treatment enhanced intracellular level of ROS and activated AMPK. AMPK activation 
decreased expression of Sp1 which subsequently suppressed DNMT1 expression. Down-
regulation of DMNTI induced apoptosis and suppressed metastasis [57].  MDA-MB-231 cells 
treated with PG led to the inhibition of AMPK which in turn decreased the level of Sp1 protein 
and subsequently reduced the expression of DNMT1. Down-regulation of DMNTI reduced 
mesenchymal markers expression and boosted the E‐cadherin expression, thus, suppressed 
metastasis [49, 70]. In contrast, DNMT1 is as an upstream target of Sp1 in bladder cancerous 
cells [135]. PG suppresses metastasis by AMPK activation in HepG2 and SW620 cells while 
AMPK inhibition in MDA-MB-231 and this conflicting role of AMPK in metastasis might be 
associated with the difference in cancer but further researches are mandatory to fully 
understand AMPK signaling role in cancer. Anti-cancer activities of physcion and PG are 
summarized in Table 2(a) and Table 2(b), respectively. 
 
Table 3 (a) Anti-cancer activities of physcion 
Cancer type Cell line No. of cells 
Treatmen
t time 







5×103 cells/well 24h, 48h 5, 10 μM 
↑Cleaved caspase-3, ↑Bax, 
↓Bcl-2, ↑LC3B II, ↑Beclin-1, 








24h, 48 h, 
72h 



















5 × 105 cells/well --- --- 
↑Caspase-3, ↑PARP, 






5 × 104 cells/ml 72 h 45.4 μM 
↓Cyclin A/D/E, ↓CDK2, 
↑CDK4, ↓PCNA, ↑p21, ┴c-
Myc, ┴Rb, ↑caspase-3/-8/-9, 









24h, 48h 10, 20 μM 
↓Cyclin D1,↓Cyclin E, ↑p21, 
↑p27, ↑Caspase-3, ↑Cleavage 
of PARP,↑caspase-9, 
↑TRAIL, ↑Fas, ↑DR5, ↓Sp1, 
↑ROS, ↑LC3B-II, ↓p62, 
↑ZBTB10, ↓miR-27a 
G1 [26] 





↓N-cadherin, ┴Snail, ┴Twist, 
┴Slug, ↑ROS, ↑p-AMPK, 
↑GSK3β, ↓SOX2 
HCT116 5×103 cells/well 
24h, 48 h, 
72h 
1.25, 2.5, 5 
μM 








5×103 cells/well 24h --- 
↑ROS, ↑Caspase-3 and -9, 


















↑Caspase-3, ↓p-Akt, --- [28] 
Gastric SGC-7901 --- 
24h, 48h, 
72h 
1.25, 2.5, 5 
μM 
↓Cyclin A, ↓Cyclin B1, 







--- --- 40 µM 







0 to 100 
μM 









       
 
 Table 3 (b). Anti-cancer activities of PG 
Cancer type Cell line No. of cells 
Treatment 
time 







--- --- --- 
↑Caspase-3, ↑PARP, 
↑Caspase-9, ↓PIM1, ↓Bcl-2, 
↓Bcl-xL, ↑Bax 
--- [89] 
 HepG2 5×103 cells/well 
24h, 48 h, 
72h 
--- 











1×105 cells/ml 24h, 48h 10, 20 μM 
↑Caspase-3, ↑Cleaved PARP, 






















5,  10 μM 
↑Caspase-3, ↑PARP, ↓Bcl-2, 
↑Bax, ↓Cyclin D1, ↓Cyclin 
A, ↑p21/27, ┴SphK1 at 









↓Ki-67 protein, ↑CDK2, 







Glioblastoma U87, U251 1×104cells --- --- 



















Colorectal HCT116 cells 1.2×105 cells/ml --- --- 
↑E‐cadherin, ↓Vimentin, 
↓N-cadherin, ┴EMT, 
↓Fibronectin, ↓Snail, ↓Slug, 













↑PARP, ↑ROS, ↓miR-27a , 













24h, 48h or 
72 h 
10, 20, 50 
μg/ml 
↑Bax, ↓Bcl-2, ↓miR-21, 
↑Caspase-3/-9, ↑PTEN, 
↓p-GSK3β, ↓p-Akt, ↓miR-21, 
↓Survivin 
--- [90] 
Up-regulation  ↑, Down-regulation ↓, Inhibition ┴, Activation Act
 
3.1.5 Induction of autophagy by physcion 
Autophagy is defined as type-II programmed cell death and is distinguished by the production of 
autophagy vacuoles in the cytoplasm. It is a response of cancerous cells towards different anti-
cancer treatments. Recent evidences have shown that natural bioactive compounds are involved 
in modulating autophagy via inhibiting or inducing various transcriptional factors and cellular 
signaling pathways [136-137]. Physcion induced autophagy in SMMC7721 and Hep3B cells 
which was evident by the decreased level of p62 and increased level of autophagy markers Atg5 
(Autophagy related 5), Beclin1 and LC3B-II, autolysosomes and autophagosomes. Physcion 
induced autophagy involves JAK2/STAT3 (Janus kinase 2/signal transducer and activator of 
transcription 3) signaling. Physcion reduced phosphorylation of JAK2 and STAT3, thus, 
inactivating JAK2/STAT3 pathway.  
Regarding metastasis, autophagy can have pro-metastatic or anti-metastatic action. Blocking 
autophagy abrogated the anti-metastatic effects of physcion in liver cancer cells, indicating its 
anti-metastatic role [23]. Physcion also stimulated autophagy in CNE2 nasopharyngeal cells 
which is noticeable by increased LC3B-II and decreased p62 levels [26]. Pro-autophagic effects 
on osteosarcoma cells have been reported by ROS generating agents [138-139] and PG is known 
to induce ROS mediated apoptosis in osteosarcoma, so, research in this regard is needed that PG 
might also inhibit proliferation of osteosarcoma cells via inducing autophagy. 
3.1.6 Synergistic effects of physcion  
Currently, mono-drug therapy is not a conventional therapeutic approach for treating diseases 
with intricate pathophysiology such as AIDS and cancer where single drug proves less effective, 
so, the conservative approach of “one disease, one drug, one target” has been shifted towards 
multi-drug therapy [140]. Sorafenib’s anti-proliferative effects in Huh and HepG2 cells were 
enhanced by physcion treatment. Physcion with sorafenib down-regulated Notch 3 expression 
which in turn decreased the level of p-Akt, thus, repressing Notch 3/Akt signaling [141]. 
Leukemic K562/ADM cells are resistant to adriamycin and have significantly down-regulated 
miR-146a expression associated with elevated expression of CXCR4 (C-X-C chemokine 
receptor type 4) (miR-146a target). Drug resistance to adriamycin was reversed by physcion via 
elevating the expression of miR-146a hence, down-regulating CXCR4 expression. Physcion also 
impeded binding between CXCR4 and CXCR12 to impair migration [142]. 
3.1.7 Physcion as inhibitor of 6-phosphogluconate dehydrogenase (6PGD) 
 
Reprogrammed cell metabolism generally exists in different types of cancerous cells. These 
abnormal changes in metabolism provide energy as well as metabolic intermediates which are 
essential for the increased proliferation of cancer cells. Various investigations have revealed that 
cancer cells overexpress oxidative pentose phosphate pathway enzymes to support cellular 
growth and survival. 6-phosphogluconate dehydrogenase (6PGD) is the 3rd enzyme in the 
oxidative PPP (pentose phosphate pathway) that converts 6-phosphogluconate to ribulose-5-
phosphate (Ru-5-P) and generates NADPH to control redox status in the mammalian cells [143]. 
Over-expression of 6PGD has been documented to be involved in several cancers such as lung, 
thyroid, cervical intraepithelial neoplasia, and colorectal cancers. Prohibition of 6PGD causes 
decreased cellular proliferation and H2O2-induced cell death, probably due to scarcity of 
formation of reducing power NADPH. Thus, 6PGD acts as a novel promising target to overcome 
chemotherapeutic resistance [144-147].  
Physcion and its derivative S3 acted as 6PGD inhibitors with IC50 values of about 17.8 µM and 
38.5 µM, respectively, while Kd value of interaction between S3-6PGD and physcion-6PGD 
were found to be 17.1 µM and 26.0 µM, respectively. Molecular docking showed that physcion 
attaches to a pocket near 6-PG binding site surrounded by residues Lys 76, Met 15, His 452, and 
Lys 261 of 6PGD and creates hydrophobic interaction with them as well as with Asn 103 forms 
hydrogen bond via its 10 keto group. Treatment of K562 cells with physcion and H1299 cells 
with S3 for 12 h decreased ratio of NADPH/NADP+, levels of Ru-5-P, biosynthesis of lipids, 
RNA and PPP oxidative flux while increased intracellular level of 6-PG without triggering 
apoptosis. Enhanced p-AMPK, p-ACCA1 (Acetyl-coenzyme A carboxylase carboxyl 
transferase), intracellular levels of ATP, lactate formation, and LKB1 (liver kinase B1) complex 
disruption was found in H1299 cells treated with physcion or S3. LKB1-deficient A549 cells 
showed decreased expression of Ru-5-P and 6PGD activity without affecting lipogenesis and 
phosphorylation of AMPK. HFF and HaCaT cells reduced the levels of Ru-5-P and 6PGD 
activity upon physcion treatment while lipogenesis was decreased along with enhanced p-AMPK 
[146]. Inhibition of 6PGD by physcion in HCC cells reduced cellular growth and triggered 
apoptosis. Furthermore, physcion also considerably increased the pro-apoptotic and anti-
proliferative effects of cisplatin, doxorubicin and paclitaxel in HCC cells [148]. Physcion 
suppressed 6PGD activity in CaLo and CaSki cervical cells. Inhibition of 6PGD enhanced 
apoptosis while migration and proliferation were significantly down-regulated in cervical 
 
carcinoma cells. Physcion activated AMPK which suppressed 6PGD and in turn decreased the 
activity of Rac1 and RhoA, both having cell migratory roles [149]. Inhibition of 6PGD by 
physcion sensitized the response of breast cancer to chemotherapeutic agents as evident from 
increased death and reduced growth of breast cancer cells upon exposure to combined treatment 
with physcion and doxorubicin or paclitaxel as compared to single drug treatment. Inhibition of 
6PGD by physcion was brought about by the activation of AMPK which in turn inhibited ACC1 
by phosphorylating it at S79. Prohibition of ACC1 results in significantly reduced lipid 
biosynthesis [150]. It is noted that AMPK inhibition in HCC, breast and cervical cancer cells 
attenuated the physcion induced effects suggesting prohibition of 6PGD acts on HCC, breast and 
cervical cancer cells by activation of AMPK. [148-150]. DHA and physcion synergistically 
reduced proliferation and triggered apoptosis in K562 cells without causing hemolysis. Halting 
the viability of leukemia cells was neither due to induced oxidative stress nor by COX2 
(cyclooxygenase-2) inhibition. Rather, physcion and DHA activated AMPK which in turn 
inhibited ACC1 by phosphorylating it and resulted in reduced cellular proliferation and 
attenuated biosynthesis of lipids [147]. Ru-5-P formation by 6PGD prevents activation of AMPK 
through disruption of the LKB1 active complex [146]. Physcion and DHA treated cells showed 
reduced level of Ru-5-P and elevated activity of LKB1 suggesting LKB1 as the upstream AMPK 
activator with synergistic drug treatment and the effect of physcion and DHA was mainly 
mediated via ribulose-5-phosphate dependent regulation of LKB1 in cells [147]. Thus, treatment 
combined with physcion and DHA may serve as a treatment strategy against leukemia with no 
hemolysis. Thus, future studies are recommended to further investigate the role of combinatorial 
treatment of physcion with chemo-drugs in halting metastasis and chemo-sensitization of cancer 
cells as 6PGD is an important mediator of metastatic transformations and drug resistance in 
cancer. Being a nutraceutical, intake of dietary supplements of physcion with chemotherapy 
might have potential to reduce the side effects of chemotherapy and enhance the efficacy of 
cancer drugs.  
3.1.8 Other molecular targets associated with anti-cancer activity of physcion and PG 
Physcion triggered necrosis and caspase independent apoptosis in cervical C33A and SiHa as 
well as oral HSC-3 carcinoma cells by inducing various cellular events. Treatment with physcion 
caused high oxidative stress and induced irreversible DNA injury during cell cycle in cervical 
cancer cells. Physcion inhibited Akt in HSC-3 cells as compared to cervical cancer cells. 
 
Oxeiptosis and many other cell deaths have been linked with increased oxidative stress. Reactive 
oxygen and nitrogen species interact with physcion to alter the concentration of •NO and H2O2, 
therefore, affecting the activity of enzymes such as superoxide dismutase and NADPH oxidase 1 
[28]. In the case of limited DNA damage, PARP-1 repairs DNA by catalyzing ADP-ribosylation 
using NAD+ which is then regenerated using adenosine triphosphate. If DNA is not repaired, cell 
undergoes apoptosis via caspase dependent pathway. On the contrary, extensive DNA damage 
may lead to necrosis as continuous PARP-1 activation exhaust ATP and  NAD+ stocks so, ATP 
dependent caspase pathways cannot be initiated [151]. Physcion treatment led to the down-
regulation of HOXA5 in NALM6 and SUPB15 cells which then increased Bax and decreased 
Bcl-2 level leading to mitochondrial apoptosis [25]. SphK1 (sphingosine kinase 1), an enzyme 
involved in the regulation of the ceramide/S1P balance, is inhibited at translational level by PG, 
thus, significant increase in the ceramide/S1P ratio results when intracellular level of ceramide 
increases while that of SIP1 decreases which resulted in enhanced apoptosis in human SUPB15 
and NALM6 cells [69]. As the up-regulation of miR-124 by PG is evident in melanoma [117] 
and SphK1 is documented as a direct target of miR-124 in various cancerous cells [113, 152], 
therefore, research in this regard is needed whether SphK1 expression by PG is down-regulated 
due to increased expression of miR-124 or not. PG anti-neoplastic effects in Bel7402 and 
SMMC7721 cells were linked with dose dependent suppression of mRNA expression and protein 
level of PIM1 (Proto-oncogene serine/threonine-protein kinase 1) along with its downstream 
targets Bcl-2 and Bcl-xL [89]. Furthermore, PG activates apoptosis in lung cancer cells via 
mitochondrial pathway by up-regulation of PPARγ (Peroxisome proliferator-activated receptor 
gamma) at transcriptional and translational levels [71]. In ACHN and RCC4 cells, PG inhibited 
glycolysis and induced apoptosis via suppressing HK2 (hexokinase 2) expression. Glycolysis 
inhibition was evident from the decreased lactate production and glucose consumption. PG 
decreased HK2/VDAC (voltage dependent anion channel) binding and former’s mitochondrial 
fraction by enhancing its dissociation from mitochondrial membrane and increasing its cytosolic 
fraction, thus, redistributing HK2 [73]. The molecular targets and mechanisms of action of 
physcion and PG have been displayed in Figure 3 and Figure 4, respectively. 
 
 




Figure 4. Representation of molecular mechanisms of actions associated with anti-cancer activity of physcion and PG
 
3.2 In vivo studies and safety profiling 
Physcion treatment at the dosage of 20 and 40 mg/kg/day resulted in apoptotic cell death dose 
dependently in xenograft model which was established by injecting Huh7 cells into left flanks. 
Physcion treatment didn’t affected total body mass of the xenograft mouse model. The 
mechanism of action of physcion involves activation of ER stress via reduced level of Ki-67 
along with enhanced level of activated caspases-3/-12 and CHOP [40]. Physcion inhibited tumor 
growth and stimulated apoptosis at the dosage of 20 and 40 mg/kg/day in BALB/c xenograft 
mice model established by inoculation of HepG2 cells. Physcion treatment caused up-regulation 
of miR-370, increased p-AMPK while significantly decreased Sp1 and DNMT1 expression 
suggesting the antitumor efficacy of physcion via modulating AMPK/Sp1/DNMT1 signaling 
pathway [24]. Results from in vivo investigation on pulmonary metastasis model of 
hepatocellular carcinoma showed that physcion treatment decreased tumor size, tumor weight 
and pulmonary metastasis in a dose dependent mode (20 and 40 mg/kg/ day) without affecting 
total body weight and normal body tissues [23]. In CNE2 injected xenograft mouse model, 
physcion suppressed tumor growth without influencing total body weight and caused autophagy 
and apoptotic cell death as evident by increased level of LC3B-II and cleaved caspase-3. 
Inhibition of tumor growth was linked to reduced miR-27a and SP1 expressions [26]. In another 
in vivo investigation, combinatorial treatment of physcion and sorafenib enhanced caspase-3 
activity and repressed Notch/Akt signaling as compared to sorafenib alone [141]. Physcion in 
combination with adriamycin reversed drug resistance in K562/ADM cells. Physcion enhanced 
antitumor effect of adriamycin by upregulating miR-146a expression which then suppressed the 
expression of CXCR4 [142]. Physcion in combination with paclitaxel inhibited tumor growth in 
xenograft mouse model (established by inoculation of MDA-MB-231 cancer cells) more 
effectively as compared to physcion or paclitaxel alone [150]. Treatment with S3 (physcion 
derivative) at dose of 20 mg kg−1 d−1  reduced 6PGD activity, Ki-67 expression and tumor growth 
without causing toxic effects in xenograft models injected with H1299 cells, Tu212 cells and 
K562 cells which further validates the in vivo efficacy S3 as a metabolic inhibitor [146]. Human 
K562 cells inoculated-xenograft model showed significantly reduced tumor growth when treated 
with DHA (dihydroartemisinin) and S3 at dose of 2.5 mg/kg/day and 5 mg/kg/day respectively 
for 15 days. Intraperitoneal administration of this dose caused reduced tumor growth 
accomplished by activation of AMPK without any adverse effect on hematopoietic properties of 
 
xenograft model as no alterations in RBC and hemoglobin count were found. Moreover, 
histological studies show that DHA + S3 administration did not induce any noticeable damage to 
heart, kidney, liver or bone marrow tissues of mouse model. More interestingly, physcion + 
DHA treatment remarkably reduced the growth of primary leukemia cells from a leukemia 
patient while this treatment didn’t exerted any effect on the viability of WBCs and RBCs from a 
healthy human donor which further validates its anti-leukemia potential [147]. Leukemia’s are 
most common and deadliest forms of cancer, thus, physcion’s potential against leukemia should 
be further investigated in patient-derived cancer xenografts and preclinical trials in combination 
with chemo-drugs.  
PG has been investigated in lung metastatic mouse model established through injecting 
MDA‐MB‐231 cells by tail vein of 3-4 weeks old female nude mice. Histological analysis 
showed that PG lowered the metastatic pulmonary tumor amount and micro-
metastatic nodules number per field at both 20 and 50 mg/kg dosage after 3 weeks of injection 
and this anti-metastatic effect was linked by p-AMPK along with SP1 and DNMT1 down-
regulation, thus, supporting in vitro studies [49]. It displayed anti-leukemic activity in xenograft 
model of mouse generated by inoculating NALM6 cells into 2 months old NSI mice through 
angular veins. PG prolonged survival of xenograft model and resulted in tumor reduction evident 
by reduced weight of spleen at both 20 and 40 mg/kg [69]. PG at a dose of 40 and 80 mg/kg 
delayed tumor growth, increased activation of caspase-3 and repressed PIM1 expression in tumor 
tissues suggesting apoptosis induction via PIM1 modulation in xenograft mice model using HCC 
cells, thus, in vivo results correlate with in vitro findings [89]. Investigation of PG efficacy 
against NSCLC has shown delayed tumor growth, dose dependent increase in apoptosis with 
significant increase in caspase-3 and PPARγ,  activation as revealed via IHC assay [71]. The in 
vivo anti-ccRCC effect of PG demonstrated significant tumor growth suppression at a dose of 40-
80 mg/kg without changing body weight of murine model indicating its general safety. In vitro 
results are supported by the fact of increased apoptosis associated with reduction in HK2 
expression in the tumor tissues [73]. PG prohibited tumor progression in nude mice grafted with 
KB cells in dose dependent way (10, 20, 40 mg/kg/day). The inhibitory effect was linked with 
marked downregulation of survivin and miR-21 expression and significant up-regulation of 
PTEN [90].  
  
 
4. Conclusions and future recommendations 
This review highlights the anti-cancer research progress of both physcion and PG in many in 
vitro and in vivo models of cancer. Data obtained from various investigations have shown that 
physcion and PG are potential anti-cancer agents. They trigger apoptosis, cause cell cycle arrest 
and inhibit metastasis in various cancers via interfering with different cellular mechanisms which 
are pivotal in the development of cancer and its progression. Physcion induced autophagy acts as 
both pro-apoptotic and pro-survival factor in different cancers. Physcion acts as potent inhibitor 
of 6PGD and can be used synergistically with chemo-drugs such as adriamycin to enhance their 
anti-cancer effects and to prevail over drug resistance. In vivo studies on physcion indicated its 
general safety as non-toxic compound. However, safety profiling was largely focused on their 
effect on body weight of animal while very few studies provide histological analysis of tissues 
from various organs, thus, future researches should focus on the exploration of hepatotoxicity, 
nephrotoxicity and cardiotoxicity of physcion as well as its effects on serum chemistry. Various 
studies report the anti-cancer potential of physcion in cell-line derived xenografts, thus, physcion 
and its derivatives should also be explored in patient-derived cancer xenografts in future studies. 
Further research should be conducted to determine the safe dosage of physcion and PG for 
therapeutic implications. Natural dietary sources of physcion should also be explored for the 
preparation of nutraceutical supplements for cancer patients. Furthermore, pharmacokinetics, 
pharmacodynamics, drug metabolism and bioavailability of physcion and its derivatives also 
needs to be investigated. Although physcion and PG possess good potential against various 
cancers, however, preclinical and clinical trials are yet mandatory to completely figure out their 
potential in order to establish these compounds as lead candidates for cancer therapies. 
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